hemodialysis patients. End-stage renal disease
Conditions
Interventions
Intervention 1: daily prescription of 1000 mg of omega-3 capsule for 10 weeks to the study group. Intervention 2: daily prescription of one placebo capsule containing sunflower oil to the control grou
Treatment - Drugs
daily prescription of 1000 mg of omega-3 capsule for 10 weeks to the study group
daily prescription of one placebo capsule containing sunflower oil to the control group for 10 weaks
Sponsors
Vice Chancellor for Research Affairs, Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criterias: patient's willingness to cooperate, and at least 6 months of dialysis starting time. Exclusion criterias: presence of bleeding and warfarin anticoagulation drugs usage or anti-thrombotic (aspirin, ticlopidine, dipyridamole and clopidogrel); diabetes; hepatitis, and other infectious diseases; body mass index less than 18.5 or more than 30 kg/ m2; steroidal and non-steroidal anti-inflammatory drugs; omega-3 fatty acids supplements and vitamins E or C within two months before the study .
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cholestrol. Timepoint: week,0,10. Method of measurement: by cell counter.;Triglycerid. Timepoint: week,0,10. Method of measurement: by sell counter.;H.d.L. Timepoint: week,0,10. Method of measurement: by cell counter.;L.D.L. Timepoint: week,0,10. Method of measurement: by cell counter.;Serum alboumin. Timepoint: weak ,0,10. Method of measurement: by sell counter. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed